Javascript must be enabled to continue!
1081 Psychiatric Symptoms and Nicotine use in Insomnia Following Traumatic Brain Injury
View through CrossRef
Abstract
Introduction
Insomnia following Traumatic Brain Injury (TBI; TBI insomnia) is a common problem, with prospective studies finding that more than half of individuals developed insomnia within the first three months of injury. Individuals with TBI are also at higher risk for psychiatric symptom development and demonstrate greater nicotine use (OR= 2.15) compared to individuals without a history of TBI. Nicotine use is further associated with disrupted sleep, negatively impacting sleep through its effects on arousal-promoting neurotransmitters (e.g., dopamine, norepinephrine, acetylcholine, etc.), sympathetic nervous system activation, potential circadian dysregulation, and sleep architecture disruption. And yet, despite greater rates of psychiatric symptoms and nicotine use following TBI and the deleterious impacts of nicotine use on sleep, to our knowledge no work has explored the associations of nicotine status and psychiatric symptoms with sleep in individuals with TBI insomnia.
Methods
We analyzed baseline data from a community sample of TBI patients with insomnia (N=48, Mage=39.8 ±12.9, 65% female) enrolled in a parent RCT comparing 4-session CBT-I to sleep education. Participants self-reported nicotine use, with 15% and 17% (N=7 and 8) endorsing current and former nicotine use. Hierarchical multiple regression examined the associations between 1) psychiatric symptoms and subjective sleep quality and 2) psychiatric symptoms, nicotine use status, and subjective sleep quality.
Results
On average, participants endorsed mild anxiety symptoms (MGAD-7: 6.4 ±5.2), moderate depressive symptoms (MPHQ-9: 10.1 ±5.2), and poor sleep quality (MPSQI: 12.4 ±3.2). In the initial model, psychiatric symptoms were significantly associated with worse subjective sleep quality (F(2, 45)=6.33, p=0.004, R2=0.22). Adding nicotine use status in the second model significantly improved model fit (p=0.03, ∆R2=0.11). After adjusting for psychiatric symptoms, subjective sleep quality differed significantly by nicotine use status, with current nicotine users reporting significantly worse sleep quality than never users (p=0.041).
Conclusion
Individuals with TBI insomnia who currently use nicotine are at greater risk for worse sleep quality and greater sleep disturbances, even after accounting for co-occurring anxiety and depressive symptoms. These findings highlight the importance of targeted screening and policy efforts to reduce nicotine exposure, address psychiatric symptoms, and improve insomnia outcomes following TBI.
Support (if any)
AASM Foundation SRA I.
Oxford University Press (OUP)
Title: 1081 Psychiatric Symptoms and Nicotine use in Insomnia Following Traumatic Brain Injury
Description:
Abstract
Introduction
Insomnia following Traumatic Brain Injury (TBI; TBI insomnia) is a common problem, with prospective studies finding that more than half of individuals developed insomnia within the first three months of injury.
Individuals with TBI are also at higher risk for psychiatric symptom development and demonstrate greater nicotine use (OR= 2.
15) compared to individuals without a history of TBI.
Nicotine use is further associated with disrupted sleep, negatively impacting sleep through its effects on arousal-promoting neurotransmitters (e.
g.
, dopamine, norepinephrine, acetylcholine, etc.
), sympathetic nervous system activation, potential circadian dysregulation, and sleep architecture disruption.
And yet, despite greater rates of psychiatric symptoms and nicotine use following TBI and the deleterious impacts of nicotine use on sleep, to our knowledge no work has explored the associations of nicotine status and psychiatric symptoms with sleep in individuals with TBI insomnia.
Methods
We analyzed baseline data from a community sample of TBI patients with insomnia (N=48, Mage=39.
8 ±12.
9, 65% female) enrolled in a parent RCT comparing 4-session CBT-I to sleep education.
Participants self-reported nicotine use, with 15% and 17% (N=7 and 8) endorsing current and former nicotine use.
Hierarchical multiple regression examined the associations between 1) psychiatric symptoms and subjective sleep quality and 2) psychiatric symptoms, nicotine use status, and subjective sleep quality.
Results
On average, participants endorsed mild anxiety symptoms (MGAD-7: 6.
4 ±5.
2), moderate depressive symptoms (MPHQ-9: 10.
1 ±5.
2), and poor sleep quality (MPSQI: 12.
4 ±3.
2).
In the initial model, psychiatric symptoms were significantly associated with worse subjective sleep quality (F(2, 45)=6.
33, p=0.
004, R2=0.
22).
Adding nicotine use status in the second model significantly improved model fit (p=0.
03, ∆R2=0.
11).
After adjusting for psychiatric symptoms, subjective sleep quality differed significantly by nicotine use status, with current nicotine users reporting significantly worse sleep quality than never users (p=0.
041).
Conclusion
Individuals with TBI insomnia who currently use nicotine are at greater risk for worse sleep quality and greater sleep disturbances, even after accounting for co-occurring anxiety and depressive symptoms.
These findings highlight the importance of targeted screening and policy efforts to reduce nicotine exposure, address psychiatric symptoms, and improve insomnia outcomes following TBI.
Support (if any)
AASM Foundation SRA I.
Related Results
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
1127 Nicotine Use and Subjective Sleep Quality Among Individuals with Traumatic Brain Injury
1127 Nicotine Use and Subjective Sleep Quality Among Individuals with Traumatic Brain Injury
Abstract
Introduction
Combustible cigarettes are the leading cause of preventable death in the U.S. Nicotine use prevalen...
Plasma Nicotine Pharmacokinetics of Oral Nicotine Pouches Across Varying Flavours and Nicotine Content *
Plasma Nicotine Pharmacokinetics of Oral Nicotine Pouches Across Varying Flavours and Nicotine Content *
SUMMARY
Background
In recent years several nicotine products have been introduced that aim to offer smokers an alternativ...
Rodent models for nicotine withdrawal
Rodent models for nicotine withdrawal
Background:
Animal models are critical to improve our understanding of the neuronal mechanisms underlying nicotine withdrawal. Nicotine dependence in rodents ca...
Correlates of the Use of Nicotine Pouches to Quit Other Nicotine and Tobacco Products among United States Adults: Results from the Population Assessment of Tobacco and Health Study Wave 7 (2022-2023)
Correlates of the Use of Nicotine Pouches to Quit Other Nicotine and Tobacco Products among United States Adults: Results from the Population Assessment of Tobacco and Health Study Wave 7 (2022-2023)
Abstract
Background
As nicotine pouches are increasingly adopted as a harm reduction method for tobacco cessation, it is ...
Associations of nicotine concentration levels in e-cigarettes and tobacco dependence among US adults
Associations of nicotine concentration levels in e-cigarettes and tobacco dependence among US adults
Abstract
Introduction
Nicotine concentration level, a key characteristic of modern e-cigarettes, may affect dependence ri...
The Transfer of Nicotine from Nicotine Salts to Mainstream Smoke
The Transfer of Nicotine from Nicotine Salts to Mainstream Smoke
Abstract
Transfer of nicotine to mainstream smoke was measured for Reference cigarettes made with the addition of 20 -40 mg of seven different nicotine salts, d- and...
Identification and Quantitation of Nicotine Polacrilex in Nicotine Pouches and Other Oral Nicotine Delivery Products
Identification and Quantitation of Nicotine Polacrilex in Nicotine Pouches and Other Oral Nicotine Delivery Products
SUMMARY
Nicotine polacrilex (CAS-No. 96055-45-7) can be used as the source of nicotine in nicotine pouches and other oral nicotine delivery p...

